Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | The genetics of breast cancer complete response

Sandra Swain • 3 Jun 2019
ASCO 2019
Breast Cancer
NSABP B-41

Sandra Swain, MD, FASCO, of the Georgetown University Medical Center, Washington, DC, explains the genes and signatures associated with pathologic complete response in the NSABP B-41 breast cancer (NCT00486668) study at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Sandra Swain

2:43
CLEOPATRA & EMILIA: HER2+ mBC state-of-the-art
Sandra Swain • 7 May 2020
1:56
NSABP B-41: genes and signatures associated with pCR
Sandra Swain • 7 May 2020
2:40
CLEOPATRA: pertuzumab, trastuzumab & chemo for HER2+ mBC
Sandra Swain • 8 May 2020
2:37
Remarkable data: trastuzumab deruxtecan for HER2+ BC
Sandra Swain • 13 May 2020

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals